STRIDE Regimen Extends Survival in Unresectable Hepatocellular Carcinoma
The median overall survival was 16.4 months with STRIDE and 13.8 months with sorafenib.
Hepatocellular Carcinoma
TACE Improves Efficacy of Lenvatinib in Advanced Hepatocellular Carcinoma
TACE improved responses and survival outcomes.
Guideline Issued for External Beam RT in Primary Liver Cancers
EBRT is strongly recommended as a potential first-line therapy for patients with HCC confined to the liver who are not candidates for curative therapy.
First-Line Nivolumab Does Not Improve Survival in Advanced Hepatocellular Carcinoma
Overall survival results with nivolumab were similar to results with sorafenib.
Are Immune Checkpoint Inhibitors Better Than Standard Care for Unresectable HCC?
Patients who received immune checkpoint inhibitors had better overall and progression-free survival.
Immune Checkpoint Inhibitors May Not Benefit Trial-Ineligible Cancer Patients
The restricted mean survival times were similar at 12 months and 36 months.
ASTRO: EBRT Underused in Liver Cancer Patients Awaiting Transplant
Only 3.6% of patients received external-beam radiation therapy alone or in combination with other liver-directed bridging therapies.
Sintilimab Plus IBI305 for Hepatitis B Virus-Positive Hepatocellular Carcinoma
The combination of sintilimab and IBI305 improved progression-free survival in patients with unresectable hepatocellular carcinoma.
Better Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma
The combination bested sorafenib.
Donafenib Bests Sorafenib in Chinese Patients With Advanced Hepatocellular Carcinoma
Overall survival was superior with donafenib.
- Loading...
Loading...
Next post in Gastrointestinal Cancers
Loading... 
Loading...